Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

31.14 +2.25 (+7.81%)
Streaming Delayed Price Updated: 10:43 AM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vera Therapeutics, Inc. - Class A Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
7 Stocks That Wall Street Analysts Are Loving in June ↗
Sometimes, it’s better to get your ideas from the experts. Thus, if you lack time, these top analyst recommend stocks could be enticing. 
Via InvestorPlace
News headline image
Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Recap: Vera Therapeutics Q1 Earnings ↗
 
Via Benzinga
News headline image
HC Wainwright & Co. Maintains Buy Rating for Vera Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Why Vera Therapeutics Stock Bolted Higher This Week ↗
Vera's stock gained a noteworthy 49% this week. 
Via The Motley Fool
News headline image
Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs
From Vera Therapeutics
Via GlobeNewswire
News headline image
$12M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗
Although US stocks closed mixed on Monday, there were a few notable insider trades. 
Via Benzinga
What 4 Analyst Ratings Have To Say About Vera Therapeutics ↗
 
Via Benzinga
News headline image
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
From Vera Therapeutics
Via GlobeNewswire
News headline image
$12M Bet On Vera Therapeutics? Check Out These 3 Stocks Insiders Are Buying ↗
Although US stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! 
Via InvestorPlace
News headline image
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Releases Interim Analysis Of Rare Kidney Disease Drug, Deprioritizes Certain Phase 3 Programs ↗
Vera Therapeutics Inc (NASDAQ: VERA) has announced results from a prespecified per-protocol (PP) analysis of the Phase 2b ORIGIN trial of atacicept in IgA nephropathy (IgAN) patients. 
Via Benzinga
News headline image
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)
From Vera Therapeutics
Via GlobeNewswire
News headline image
5 Cheapest Health Care Stocks You Should Think About ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vera Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
Top 5 Health Care Stocks That May Surge ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  On Thursday, 63 companies set new 52-week lows. 
Via Benzinga
News headline image
Dow Gains 150 Points After Fed Minutes ↗
U.S. stocks traded higher toward the end of trading, following the release of minutes from the FOMC meeting. 
Via Benzinga
News headline image
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.